The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | The impact of renal impairment on clinical outcomes with mezigdomide plus dex in R/R myeloma
Suzanne Trudel, MSc, MD, University of Toronto Princess Margaret Cancer Centre, Toronto, Canada, discusses the findings of a study that investigated the impact of renal impairment on the clinical outcomes with mezigdomide, a novel oral cereblon E3 ligase modulator (CELMoD), plus dexamethasone (dex) in patients with relapsed/refractory (R/R) multiple myeloma (MM). Renal dysfunction did not compromise the efficacy of the treatment, and the safety profile was comparable to that seen in the intend-to-treat population. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
